Prevention, treatment and care of hepatitis C virus infection among people who inject drugs

International Journal of Drug Policy

Volumn 26, Issue S1, 2015, Pages S22-S26

  Bruggmann, Philip ^a   Grebely, Jason ^b  

^a Arud Centres for Addiction Medicine   (Switzerland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hepatitis C; PWID

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT;

AWARENESS; DRUG LEGISLATION; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEPATITIS C; HUMAN; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; LAW ENFORCEMENT; MORBIDITY; MORTALITY; NOTE; PATIENT CARE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SOCIAL DISCRIMINATION; VIRUS TRANSMISSION; COMPLICATION; COST OF ILLNESS; DRUG COST; ECONOMICS; HARM REDUCTION; HEALTH CARE DELIVERY; HEALTH CARE POLICY; OPIATE SUBSTITUTION TREATMENT; ORGANIZATION AND MANAGEMENT; PREVALENCE; PREVENTIVE HEALTH SERVICE; PROCEDURES; SUBSTANCE ABUSE;

ANTIVIRAL AGENTS; COST OF ILLNESS; DRUG COSTS; HARM REDUCTION; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84923320845     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2014.08.014     Document Type: Note

References (34)

1. Aspinall E.J., Corson S., Doyle J.S., Grebely J., Hutchinson S.J., Dore G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases 2013, 57(Suppl. 2):S80-S89.
2. Bruggmann P. Accessing hepatitis C patients who are difficult to reach: It is time to overcome barriers. Journal of Viral Hepatitis 2012, 19:829-835.
3. Bruggmann P. Treatment as prevention: The breaking of taboos is required in the fight against hepatitis C among people who inject drugs. Hepatology 2013, 58:1523-1525.
4. Bruggmann P., Litwin A.H. Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all. Clinical Infectious Diseases 2013, 57(Suppl. 2):S56-S61.
5. Dimova R.B., Zeremski M., Jacobson I.M., Hagan H., Des Jarlais D.C., Talal A.H. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clinical Infectious Diseases 2012, 56:806-816.
6. Doerrbecker J., Behrendt P., Mateu-Gelabert P., Ciesek S., Riebesehl N., Wilhelm C., et al. Transmission of hepatitis C virus among people who inject drugs: Viral stability and association with drug preparation equipment. Journal of Infectious Diseases 2013, 207:281-287.
7. Gower E., Estes C., Hindman S., Razavi-Shaerer K., Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology 2014, 10.1016/j.jhep.2014.07.027.
8. Grebely J., Dore G.J. Prevention of hepatitis C virus in injecting drug users: A narrow window of opportunity. Journal of Infectious Diseases 2011, 203:571-574.
9. Grebely J., Dore G.J. What is killing people with hepatitis C virus infection?. Seminars in Liver Disease 2011, 31:331-339.
10. Grebely J., Dore G.J. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research 2014, 104C:62-72.
11. Grebely J., Prins M., Hellard M., Cox A.L., Osburn W.O., Lauer G., et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine. Lancet Infectious Diseases 2012, 12:408-414.
12. Hagan H., Pouget E.R., Des Jarlais D.C., Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: The influence of time and place. American Journal of Epidemiology 2008, 168:1099-1109.
13. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases 2011, 204:74-83.
14. Hajarizadeh B., Grebely J., Dore G.J. Epidemiology and natural history of HCV infection. Nature Reviews Gastroenterology and Hepatology 2013, 10:553-562.
15. Ly K.N., Xing J., Klevens R.M., Jiles R.B., Ward J.W., Holmberg S.D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of Internal Medicine 2012, 156:271-278.
16. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: Efficacy, side effects and complications. Gut 2006, 55:1350-1359.
17. Martin N.K., Vickerman P., Miners A., Foster G.R., Hutchinson S.J., Goldberg D.J., et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012, 55:49-57.
18. Martin N.K., Hickman M., Hutchinson S.J., Goldberg D.J., Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases 2013, 57(Suppl. 2):S39-S45.
19. Martin N.K., Vickerman P., Grebely J., Hellard M., Hutchinson S.J., Lima V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013, 58:1598-1609.
20. Martin N.K., Vickerman P., Miners A., Hickman M. How cost-effective is hepatitis C virus treatment for people who inject drugs?. Journal of Gastroenterology and Hepatology 2013, 28:590-592.
21. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R.P., et al. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-1028.
22. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des J.D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378:571-583.
23. NIH National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology 1997, 26:2S-10S.
24. Page K., Morris M.D., Hahn J.A., Maher L., Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: Using evidence to inform comprehensive prevention. Clinical Infectious Diseases 2013, 57(Suppl. 2):S32-S38.
25. Paintsil E., He H., Peters C., Lindenbach B.D., Heimer R. Survival of hepatitis C virus in syringes: Implication for transmission among injection drug users. Journal of Infectious Diseases 2010, 202:984-990.
26. Paterson B., Hirsch G., Andres K. Structural factors that promote stigmatization of drug users with hepatitis C in hospital emergency departments. International Journal of Drug Policy 2013, 24:471-478.
27. Pouget E.R., Hagan H., Des Jarlais D.C. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012, 107:1057-1065.
28. Robaeys G., Grebely J., Mauss S., Bruggmann P., Moussalli J., de Gottard A., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clinical Infectious Diseases 2013, 57(Suppl. 2):S129-S137.
29. The Global Commission on Drug Policy The negative impact of the war on drugs on public health: The hidden hepatitis c epidemic 2013.
30. Turner K.M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence. Addiction 2011, 106:1978-1988.
31. UNODC. UNODC Scientific consultation: Science adressing drugs and HIV: State of the Art of Harm reduction. 2014, United Nations Office on Drugs and Crime, Vienna, Austria.
32. van der Meer A.J., Veldt B.J., Feld J.J., Wedemeyer H., Dufour J.F., Lammert F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Journal of the American Medical Association 2012, 308:2584-2593.
33. Vickerman P., Martin N., Turner K., Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 2012, 107:1984-1995.
34. World Health Organisation Guidance on prevention of viral hepatitis B and C among people who inject drugs 2012, World Health Organisation, Geneva, Switzerland.